Use of polydocanol for preparation of medicament for treatment of bromhidrosis by dispersion gridding subcutaneous multipoint continuous injection administration

Abstract

The invention belongs to the field of medicine, and relates to application of polydocanol in preparation of medicine for treating bromhidrosis through dispersion gridding subcutaneous multipoint continuous injection application, the polydocanol is a polydocanol injection, and each milliliter of the injection contains 5-30 mg of polydocanol. The invention further provides a medicine for treating bromhidrosis through dispersion gridding subcutaneous multipoint continuous injection application. The medicine comprises polydocanol and pharmaceutically acceptable auxiliary materials. The invention has the advantages of small trauma, simplicity and convenience in operation, high safety, longer treatment effect maintenance time and the like, and the long-term relieving effective rate is greater than 80%.

Description

Technical Field

[0001] The present invention belongs to the field of medical technology and relates to the use of polidocanol in preparing a drug for treating axillary odor by continuous injection at multiple points under the skin through diffuse gridding. Background Art

[0002] Bromhidrosis is a common skin disease caused by the secretion of the apocrine sweat glands in the armpits being decomposed by bacteria on the skin, producing an unpleasant odor. Due to the abnormal odor, it often causes discomfort to others, thus affecting the patient's normal social interaction, causing psychological burden, and even affecting daily life, work, employment, and studies. Bromhidrosis is related to the secretion activity of the apocrine sweat glands in the armpits. Bromhidrosis is somewhat hereditary, and its cause is mostly after the development of the apocrine sweat glands in the armpits during puberty, the sweat and secretions secreted by the apocrine sweat glands interact with bacteria and fungi to produce short-chain fatty acids and ammonia, which produce odor.

[0003] At present, the common methods for treating axillary odor include surgery, botulinum toxin type A, laser, radiofrequency microneedle and microwave. Surgical treatment is a common treatment method for patients with axillary odor. The apocrine glands are removed surgically to fundamentally improve the patient's symptoms, but the surgery is relatively traumatic. The skin of both armpits needs to be incised, and scars are left after healing. The patient's recovery period after surgery is about 2 weeks. During this period, the armpits need to be bandaged with pressure, which affects the patient's normal life. There is a risk of necrosis of the axillary skin after surgery, and the scars are obvious after healing, which will cause traction on the upper limb activities. Botulinum toxin type A injection for the treatment of axillary odor has obvious short-term effects, but the treatment effect after injection can only last for 4-6 months on average. After 6 months, due to the disappearance of the efficacy of botulinum toxin type A, axillary odor usually recurs. Therefore, in order to achieve long-term treatment effects, repeated injections are required to maintain the treatment effect. The depth and range of physical destruction of electro-optical treatments such as laser, radio frequency microneedle and microwave are difficult to grasp. In addition, there are a large number of apocrine sweat glands, a wide distribution range and randomness. Therefore, there is a risk of omission and a high chance of postoperative recurrence. The technical requirements for the operator are also the highest. If the operation is improper, it is easy to leave extensive punctate scars after the operation and obvious local adhesions. In addition, if axillary odor recurs after surgery, it is difficult to perform surgery again. Summary of the invention

[0004] In order to solve the above problems, the present invention provides the use of polidocanol in preparing a drug for treating axillary odor by continuous injection at multiple points of subcutaneous diffuse gridding, including applying polidocanol on patients with axillary odor to treat axillary odor, and preparing polidocanol into a drug for treating axillary odor, wherein the drug includes pharmaceutically acceptable excipients. Polidocanol is commonly used in the sclerotherapy of varicose veins, and acts on the cell membrane of the epidermal cells in the blood vessels to damage them, and promotes thrombosis and vascular wall fibrosis to achieve the purpose of treatment, including the central vein, reticular vein and small varicose veins used to treat spider veins. Before the disclosure of the present invention, there has been no report on the use of polidocanol for the treatment of axillary odor. Axillary odor is caused by the secretion of the apocrine sweat glands in the armpits, which are decomposed by microorganisms to produce odor substances such as short-chain fatty acids and ammonia. The present invention uses polidocanol to produce a hardening effect after contact with the soft tissue where the apocrine sweat glands are located, inducing chemical aseptic inflammation to destroy the apocrine sweat glands under the skin of the armpits to achieve the treatment effect of axillary odor. It has the advantages of less trauma, simple operation, high safety, and long-term maintenance of the treatment effect. The long-term relief efficiency is greater than 80%. Through the new ablation treatment concept to treat axillary odor, the clinical indications of polidocanol injection have been innovated, and a new way of treating axillary odor by diffuse grid subcutaneous multi-point continuous injection has been innovated.

[0005] The present invention discloses the use of polidocanol in preparing a medicine for treating axillary odor by diffuse gridded subcutaneous multi-point continuous injection. The polidocanol is polidocanol injection, each milliliter of polidocanol injection contains 5 to 30 mg of polidocanol, and each milliliter of polidocanol injection contains 39.9 to 44.1 mg of 96% ethanol.

[0006] The present invention also discloses the use of polidocanol in preparing a medicine for treating axillary odor by continuous injection at multiple points under the skin through diffuse gridding. Polidocanol is a polyol with a chemical structural formula of C 12 H 25 (OCH2CH2) n OH, wherein n is the average degree of polymerization, when n=9, the molecular weight is about 600.

[0007] The present invention also discloses a use of polidocanol in preparing a medicine for treating axillary odor, wherein the polidocanol is a polidocanol injection, wherein each milliliter of injection contains 5 to 30 mg of polidocanol, such as 10 mg of polidocanol in 2 mL of injection, 20 mg of polidocanol in 2 mL of injection, or 60 mg of polidocanol in 2 mL of injection, preferably 20 mg of polidocanol in 2 mL of injection. The use of polidocanol in preparing a medicine for treating axillary odor includes applying polidocanol to axillary odor patients to treat axillary odor, and preparing polidocanol into a medicine for treating axillary odor, wherein the medicine includes pharmaceutically acceptable excipients. Polidocanol is commonly used in the sclerotherapy of varicose veins, and acts on the cell membrane of the epidermal cells in the blood vessels to damage them, and promotes thrombosis and fibrosis of the blood vessel wall to achieve the purpose of treatment, including central veins, reticular veins and small varicose veins for treating spider veins. Before the disclosure of the present invention, there has been no report on the use of polidocanol to treat axillary odor. Axillary odor is caused by the secretions of the apocrine sweat glands in the armpits, which are decomposed by microorganisms to produce odorous substances such as short-chain fatty acids and ammonia. The present invention utilizes the hardening effect produced by polidocanol after contact with the soft tissue where the apocrine sweat glands are located, inducing chemical aseptic inflammation to destroy the apocrine sweat glands under the skin of the armpits, so as to achieve the effect of treating axillary odor. It has the advantages of less trauma, simple operation, and high safety.

[0008] Polydocanol is a polyol with the chemical formula C 12 H 25 (OCH2CH2) n OH, where n represents the length of the carbon chain and n is the average degree of polymerization. When n=9, the molecular weight is about 600. The molecular structure of polidocanol contains multiple hydroxyl groups, which makes it have good solubility and adhesion.

[0009] In one embodiment of the present invention, preferably, the solvent of the polydocanol injection is water for injection.

[0010] In one embodiment of the present invention, it is more preferred that the solvent of the polydocanol also includes ethanol.

[0011] In one embodiment of the present invention, preferably, the polydocanol injection contains 5% ethanol by volume.

[0012] In one embodiment of the present invention, preferably, the polydocanol injection also includes potassium dihydrogen phosphate and disodium hydrogen phosphate.

[0013] In one embodiment of the present invention, it is more preferred that each milliliter of solvent contains less than 68 mg of the potassium dihydrogen phosphate, and / or each milliliter of solvent contains less than 71 mg of the sodium dihydrogen phosphate.

[0014] In one embodiment of the present invention, preferably, the degree of polymerization of the polydocanol is 8 to 10.

[0015] In one embodiment of the present invention, it is more preferred that the average degree of polymerization of the polydocanol is 9.

[0016] The present invention also discloses the use of polidocanol in preparing a medicine for treating axillary odor. After testing, the subject is diagnosed as a patient with axillary odor, and the polidocanol is administered to the subject. The polidocanol is a polidocanol injection, wherein each milliliter of the injection contains 5 to 30 mg of polidocanol, and the administration comprises the following steps:

[0017] (1) After the subject's axillary area was prepared, the skin in the sweat gland distribution area was grid-marked, with each grid being a square with a side length of approximately 1 cm;

[0018] (2) Inject the polidocanol injection solution into the deep dermis and superficial fat layer corresponding to each square of skin. For example, you can first mark the injection sites, use a disposable sterile syringe with a 1mL needle to puncture tangentially, and slowly inject the polidocanol injection solution evenly into the square grid corresponding to the injection point, the deep dermis and superficial fat layer of the skin, and ensure that when injecting the drug, the needle is always located in the deep dermis and superficial fat layer.

[0019] To ensure efficacy and safety, in one embodiment of the present invention, preferably, the total daily treatment dose should not exceed 2 mg of polidocanol per kilogram of body weight per day. For example, for a patient weighing 60 kg, this is equivalent to using 12 mL of 1% polidocanol injection (2 mL of injection contains 20 mg of polidocanol) per day, and the total amount per day does not exceed 14 mL.

[0020] The present invention also discloses a drug for treating underarm odor, which includes polidocanol and pharmaceutically acceptable excipients. "Pharmaceutically acceptable" means that it is not a biologically undesirable or otherwise undesirable substance. For example, the substance can be incorporated into a pharmaceutical composition administered to a patient without producing any significant undesirable biological effect, nor will it interact with any other ingredients contained in the composition in a harmful manner. Pharmaceutically acceptable excipients (such as pH adjusters, suspending agents, surfactants, etc.) preferably meet the required standards for toxicology and finished product testing and / or have been included in the inactive ingredient guidelines established by the U.S. Food and Drug Administration.

[0021] In one embodiment of the present invention, more preferably, the pharmaceutically acceptable excipients include one or more of ethanol, potassium dihydrogen phosphate or disodium hydrogen phosphate.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The polidocanol of the present invention is used in the preparation of a medicine for treating axillary odor by continuous injection at multiple points under the skin in a diffuse grid. The polidocanol produces a hardening effect after contacting the soft tissue where the subcutaneous apocrine sweat glands are located, inducing chemical aseptic inflammation to destroy the subcutaneous apocrine sweat glands in the armpits, so as to achieve the treatment of axillary odor. The medicine has the advantages of less trauma, simple operation, high safety, and long-term maintenance of the treatment effect. The clinical treatment effect is significant, and the effective rate of long-term relief of axillary odor symptoms after injection is greater than 80%.

[0024] In the use of the polidocanol of the present invention in preparing a medicine for treating axillary odor through diffuse gridded subcutaneous multi-point continuous injection, the polidocanol injection contains polidocanol and also includes ethanol as an auxiliary material. The specific content of ethanol is not only used as a solvent. The specific content of ethanol and polidocanol have a synergistic effect to achieve significant clinical treatment effects, and the long-term relief of axillary odor symptoms after injection is more than 80%.

[0025] The present invention provides a drug for treating axillary odor, which can be treated by directly administering it through diffuse gridded subcutaneous multiple-point continuous injection, avoiding surgical incisions and possible scars, reducing the risk of infection, and the injection can be performed at multiple points, allowing the doctor to accurately control the placement of the drug or filler, and can provide a more personalized solution for specific areas or minor blemishes, without seriously damaging the original tissue structure, and relatively retaining the original characteristics of the tissue.

[0026] The use of the polidocanol of the present invention in the preparation of a drug for treating axillary odor utilizes the hardening effect produced by polidocanol after contacting the soft tissue where the subcutaneous apocrine sweat glands are located, thereby inducing chemical sterile inflammation and destroying the subcutaneous apocrine sweat glands in the armpits to achieve the therapeutic effect of axillary odor. The drug has the advantages of less trauma, simple operation, high safety, and long-term maintenance of the therapeutic effect. The clinical treatment effect is significant, and the effective rate of long-term relief of axillary odor symptoms after injection is greater than 80%. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Schematic diagram of the treatment process and effect of axillary odor patients according to Example 2 of the present invention, wherein (a) is a grid diagram of the distribution area of ​​axillary sweat glands, (b) is a schematic diagram of injection, (c) is a diagram of the appearance of axillary skin immediately after injection treatment, (d) is a diagram of the appearance of axillary skin 1 week after injection treatment, and (e) is a diagram of the appearance of axillary skin 2 weeks after injection treatment;

[0028] Figure 2 This is a picture of the appearance of the axillary skin of a patient with underarm odor in Example 3 of the present invention one week after injection;

[0029] Figure 3 This is a picture of the appearance of the axillary skin of a patient with underarm odor according to Example 4 of the present invention one week after injection. DETAILED DESCRIPTION

[0030] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.

[0031] Many specific details are set forth in the following description to facilitate a full understanding of the present invention. However, the present invention can be implemented in many other ways than those described herein, and those skilled in the art can make similar generalizations without violating the connotation of the present invention, so the present invention is not limited to the specific implementation disclosed below.

[0032] Among the existing treatment options for axillary odor, surgical treatment is a commonly used treatment method for patients with axillary odor. The apocrine sweat glands are removed surgically to fundamentally improve the patient's symptoms. However, the surgery is relatively traumatic, and incisions are required on the skin of both sides of the armpits. Scars are left after healing after surgery, and the patient's postoperative recovery period is about 2 weeks. In addition, patients with axillary odor may experience complications such as recurrence and hematoma after surgery.

[0033] In order to reduce the postoperative complications such as recurrence and hematoma in patients with axillary odor, the existing technology adopts the method of first performing surgery and then filling with foam sclerosant to reduce the postoperative complications such as recurrence and hematoma. Specifically, subcutaneous suction or removal of superficial subcutaneous fat tissue and apocrine glands is first performed, and then foam sclerosant is filled to reduce the postoperative complications such as recurrence and hematoma in patients with axillary odor. However, this method still has the problems of large trauma, large tissue damage, and high risk of infection.

[0034] The present invention provides a drug for treating axillary odor, which can be directly administered through subcutaneous multi-point injection to achieve the treatment of axillary odor, not only avoiding surgical treatment options, greatly reducing treatment risks and trauma, but also having significant clinical treatment effects, with an effective rate of long-term relief of axillary odor symptoms after injection exceeding 80%.

[0035] In addition, it should be noted that although the chemical formula of the polidocanol provided by the present invention is the same as that of the lauromacrogol in the prior art, their spatial structures are different, and they belong to two different substances. The polidocanol used in the present invention is polidocanol injection, each milliliter of polidocanol injection contains 5 to 30 mg of polidocanol, and each milliliter of polidocanol injection contains 39.9 to 44.1 mg of 96% ethanol. The specific content of polidocanol in the polidocanol injection and ethanol, as well as multi-point injection through subcutaneous route, have a synergistic effect, and the clinical treatment effect is significant. The long-term relief efficiency of axillary odor symptoms after injection is greater than 80%.

[0036] In one embodiment, the present invention provides the use of polidocanol in preparing a drug for treating axillary odor by continuous injection at multiple points through diffuse gridded skin, wherein the polidocanol is polidocanol injection, each milliliter of polidocanol injection contains 5 to 30 mg of polidocanol, and each milliliter of polidocanol injection contains 39.9 to 44.1 mg of 96% ethanol.

[0037] In one embodiment, the present invention provides the use of polidocanol in the preparation of a drug for treating axillary odor by continuous injection at multiple points through diffuse gridded skin, wherein the polidocanol is Ansoxi produced by Hameln Pharmaceuticals GmbH.

[0038] In one embodiment, the specific operation of treating axillary odor with polidocanol provided by the present invention is as follows:

[0039] 1. Preoperative preparation: Communicate with the patient and describe the surgical procedure; shave the armpit hair, use the armpit hair as the boundary, expand 1 cm outward, delineate the surgical area, and divide and mark it into 1 cm grids.

[0040] 2. Disinfection and anesthesia: Apply lidocaine ointment to the armpits 1 hour before the operation to act as an anesthetic; use iodine to disinfect the armpit skin at the beginning of the operation.

[0041] 3. Injection of polidocanol: Select a 1ml 26G syringe; perform subcutaneous multi-point fan-shaped continuous injection of polidocanol in each central area at the lower corner of the marked grid. Each grid must be evenly covered with 0.1-0.3ml polidocanol injection solution (1%). Pay attention to the injection layer, and evenly inject polidocanol at the junction of the deep dermis and subcutaneous tissue to ensure that the secretory part of the apocrine sweat glands is completely immersed in polidocanol.

[0042] 4. Follow-up treatment: After the injection, simple and appropriate bandaging, attention to care, avoid infection, follow-up observation of complications

[0043] Example 1

[0044] The clinical use of botulinum toxin type A to treat axillary odor is currently a relatively mature treatment method. Botulinum toxin type A is a neurotoxin. After being injected into the skin of the armpit, it acts on the cholinergic endings of the peripheral nerves, inhibiting the release of acetylcholine, causing the apocrine sweat glands to gradually atrophy and reduce the production of secretions, thereby achieving a therapeutic effect. The conventional surgical plan is to dilute 50U of botulinum toxin type A in 2mL of normal saline and inject it into the apocrine sweat gland area of ​​the axillary skin. In order to improve the treatment effect, the injection is repeated regularly for 2 to 3 treatment periods.

[0045] Two groups were selected respectively. The experimental group was administered with 1% polidocanol, i.e., 20 mg polidocanol in 2 mL injection. The purchased trade name was Anshuxi, the generic name was polidocanol injection (1%), the specification was 2 ml: 20 mg, and the manufacturer was Siegfried Hameln GmbH; the control group was administered with botulinum toxin type A, i.e., 50 U botulinum toxin type A in 2 mL normal saline. Twelve patients with axillary odor were selected in the experimental group, including 6 males and 6 females, with an average age of 25.0 ± 4.4 years (range 19-33 years), and 13 patients with axillary odor were selected in the control group, including 7 males and 6 females, with an average age of 25.1 ± 4.8 years (range 17-33 years). There was no significant difference in gender and age between the experimental group and the control group (P>0.05). According to the axillary odor scoring scale (TAOGS), there was no significant difference in the severity of axillary odor between the experimental group and the control group (P>0.05). All patients were grade 2 and 3, and no patients were grade 0 or 1. In the experimental group, 6 patients were grade 2 and 6 were grade 3; in the control group, 7 patients were grade 2 and 6 were grade 3. The baseline data of the patients are shown in Table 1, where P less than 0.05 indicates significance.

[0046] Table 1: Baseline data of patients with bromhidrosis

[0047]

[0048] The treatment regimen for the experimental group was:

[0049] (1) After the subject's axillary area was prepared, the skin in the sweat gland distribution area was marked with a marker pen in a grid pattern, with each grid being a square with a side length of approximately 1 cm;

[0050] (2) Inject the polidocanol injection into the deep dermis and superficial fat layer corresponding to each square of skin. For example, you can first mark the injection sites, use a disposable sterile syringe with a 1mL needle for tangential puncture, slowly inject 0.1mL of injection solution at each site, and evenly inject the polidocanol injection into the deep dermis and superficial fat layer corresponding to the square of skin corresponding to the injection point, and ensure that the needle is always in the deep dermis and superficial fat layer. If the patient's sweat gland distribution area is large, it can be increased appropriately, but the total injection amount shall not exceed 2mg of polidocanol per kilogram of body weight per day. For example, 2mL of injection solution contains 20mg of polidocanol. For a patient weighing 70kg, the daily treatment dose shall not exceed 14mL.

[0051] The treatment effects are shown in Table 2, where *: P less than 0.05 is significant:

[0052] In terms of efficacy, 7 days after surgery, the effective rates of the experimental group and the control group were 100% and 69.2%, respectively (p < 0.05), indicating that the short-term efficacy of polidocanol is better than that of botulinum toxin type A.

[0053] In the 6-month follow-up after surgery, the effective rates of the experimental group and the control group were 100% and 46.2%, respectively (P<0.05), indicating that the long-term efficacy of polidocanol in the treatment of axillary odor is better than that of botulinum toxin type A, and there is a significant difference between the two groups. The recurrence rates of the experimental group and the control group were 25.0% and 84.6%, respectively (P<0.05). The recurrence rate of the experimental group was significantly lower than that of the control group. The above clinical data show that polidocanol has advantages over traditional botulinum toxin type A in the treatment of axillary odor in terms of efficacy and recurrence rate.

[0054] In terms of adverse reactions, no patients in the experimental group or the control group experienced skin pigmentation, scarring, necrosis, infection, or hair loss. Seven days after surgery, four patients in the experimental group and two patients in the control group experienced skin redness and swelling, with no significant difference between the two groups (P>0.05). In addition, three patients in the experimental group felt pain within the first seven days after surgery, while no one in the control group felt pain (P>0.05). The above adverse reactions were all short-lived and tolerable, and all completely resolved within two weeks after surgery. Therefore, it can be considered that the polidocanol group and the control group were equivalent in terms of treatment safety, with no significant difference between the two groups.

[0055] Table 2: Clinical data on the treatment of axillary odor with 1% polidocanol and botulinum toxin type A

[0056]

[0057] *: P less than 0.05 is significant

[0058] Example 2

[0059] Male, 20 years old, had bilateral underarm sweating and odor after activities for about 8 years. Diagnosed with bilateral underarm odor, 1% polidocanol was given for bilateral underarm injection. The trade name of polidocanol is Ansoxi, the generic name is polidocanol injection (1%), the specification is 2ml:20mg, and the manufacturer is Siegfried Hameln GmbH. Prepare surgical instruments, choose a disposable 1mL sterile syringe with a needle for injection, and choose a syringe that can move smoothly and balanced to facilitate experimental operation.

[0060] Eligible patients were selected, and the skin of the axillary area was prepared. The skin of the sweat gland distribution area was marked with a marker pen, and each grid was marked with a square of approximately 1 cm in diameter. Figure 1 (a)

[0061] In the order of each site, subcutaneously inject about 0.1mL of polidocanol injection at each site. Use a disposable 1mL sterile syringe with a needle for tangential puncture, slowly inject and move the syringe needle forward and backward, and dynamically inject the liquid into the corresponding deep dermis and superficial fat layer of the square skin corresponding to the injection point, and ensure that the needle is always in the deep dermis and superficial fat layer. Figure 1 (b)

[0062] (1) Figure 1 (c) shows the appearance of the axillary skin immediately after injection treatment. It can be seen that after subcutaneous injection of polidocanol, the skin in the injection area showed acute inflammatory changes, manifested as redness, swelling and mild increase in skin wrinkles; Figure 1 (d) shows the appearance of the axillary skin 1 week after injection treatment. The axillary injection area and surrounding skin showed mild subcutaneous congestion with hemosiderin deposition. Figure 1 (e) Appearance of axillary skin 2 weeks after injection treatment. The skin appearance has returned to normal, with only a slight amount of hemosiderin remaining to be absorbed.

[0063] (2) Follow-up results: At 3 and 6 months after surgery, the symptoms of axillary sweating and odor were significantly relieved, there was no obvious pigmentation, and there was no restriction of activity.

[0064] Example 3

[0065] A 22-year-old female patient had bilateral axillary sweating and odor after activities for about 10 years. She was diagnosed with bilateral axillary odor and given 0.5% polidocanol (i.e., 10 mg polidocanol in 2 mL of injection) for bilateral axillary injection.

[0066] The injection process is the same as in Example 1. Figure 2 This is the appearance of the axillary skin one week after the injection. The axillary injection area and surrounding skin showed mild subcutaneous congestion with hemosiderin deposition. The appearance of the axillary skin returned to normal two weeks after the injection. Follow-up results: At 3 and 6 months after the operation, the symptoms of axillary sweating and odor were significantly relieved, there was no obvious pigmentation, and there was no restriction of activity.

[0067] Example 4

[0068] A 40-year-old female patient had bilateral axillary sweating and odor after activities for about 20 years. She was diagnosed with bilateral axillary osmidrosis and given 3% polidocanol (i.e., 60 mg polidocanol in 2 mL of injection) subcutaneously in both axillae.

[0069] The injection process is the same as in Example 1. Figure 3 This is the appearance of the axillary skin one week after the injection. The axillary injection area and surrounding skin showed mild subcutaneous congestion with hemosiderin deposition. The appearance of the axillary skin returned to normal two weeks after the injection. Follow-up results: At 3 and 6 months after the operation, the symptoms of axillary sweating and odor were significantly relieved, there was no obvious pigmentation, and there was no restriction of activity.

[0070] Example 5

[0071] A 38-year-old female patient had bilateral axillary sweating and odor after activities for about 18 years. She was diagnosed with bilateral axillary odor and given 2% polidocanol (i.e., 40 mg polidocanol in 2 mL of injection) for bilateral axillary injection.

[0072] The injection process was the same as in Example 1. One week after the injection, mild congestion and hemosiderin deposition were found in the axillary injection area and surrounding skin. The appearance of the axillary skin returned to normal 2 weeks after the injection treatment. Follow-up results: At 3 and 6 months after the operation, the symptoms of axillary sweating and odor were significantly relieved, there was no obvious pigmentation, and there was no activity restriction.

[0073] Example 6

[0074] A 55-year-old female patient had bilateral axillary sweating and odor after activities for about 39 years. She was diagnosed with bilateral axillary odor and was treated with bilateral axillary injection of 1.5% polidocanol (i.e., 30 mg polidocanol in 2 mL of injection).

[0075] The injection process was the same as in Example 1. One week after the injection, mild congestion and hemosiderin deposition were found in the axillary injection area and surrounding skin. The appearance of the axillary skin returned to normal 2 weeks after the injection treatment. Follow-up results: At 3 and 6 months after the operation, the symptoms of axillary sweating and odor were significantly relieved, there was no obvious pigmentation, and there was no activity restriction.

[0076] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.

Claims

1. Use of polidocanol in the preparation of a drug for treating axillary odor by continuous injection at multiple points under the skin through diffusion gridding, characterized in that: The polidocanol is polidocanol injection, each milliliter of polidocanol injection contains 5 to 30 mg of polidocanol, and each milliliter of polidocanol injection contains 39.9 to 44.1 mg of 96% ethanol.

2. Use of polidocanol in the preparation of a drug for treating axillary odor by continuous injection at multiple points under the skin through diffuse gridding, characterized in that: Polydocanol is a polyol with the chemical formula C 12 H 25 (OCH2CH2) n OH, wherein n is the average degree of polymerization, when n is 9, the molecular weight is about 600.

3. The use of polidocanol in the preparation of a medicament for treating underarm odor, characterized in that: The polidocanol described is polidocanol injection, wherein each milliliter of injection contains 5 to 30 mg of polidocanol.

4. The use according to claim 3, characterized in that The solvent of the polydocanol injection is water for injection.

5. The use according to claim 4, characterized in that The solvent of the polydocanol also includes ethanol.

6. The use according to claim 5, characterized in that The polidocanol injection contains 5% ethanol by volume.

7. The use according to claim 4, characterized in that The polydocanol injection also includes potassium dihydrogen phosphate and disodium hydrogen phosphate.

8. The use according to claim 7, characterized in that Each milliliter of the solvent contains less than 68 mg of the potassium dihydrogen phosphate, and / or each milliliter of the solvent contains less than 71 mg of the disodium hydrogen phosphate.

9. The use according to any one of claims 3 to 8, characterized in that: The degree of polymerization of the polydocanol is 8 to 10, and the chemical structural formula of the polydocanol is C 12 H 25 (OCH2CH2) n OH, where n is the average degree of polymerization.

10. The use according to claim 9, characterized in that The average degree of polymerization of the polydocanol is 9.

11. The use according to claim 10, characterized in that The drug is a drug used for being administered to the sweat gland distribution area of ​​a receptor in an effective dose so as to achieve the purpose of treating underarm odor in the sweat gland distribution area of ​​the receptor.

12. The use according to claim 11, characterized in that The administration is subcutaneous injection.

13. The use according to claim 12, characterized in that The subcutaneous injection is a point injection into the deep layer of the dermis and the superficial layer of fat.

14. Use of polidocanol in the preparation of a medicament for treating underarm odor, characterized in that: It is detected that the subject has axillary odor, and the polidocanol is administered to the subject. The polidocanol is a polidocanol injection, wherein each milliliter of the injection contains 5 to 30 mg of polidocanol.

15. A drug for treating underarm odor, characterized in that: The drug includes polidocanol and pharmaceutically acceptable excipients.

16. The drug for treating underarm odor according to claim 15, characterized in that: The pharmaceutically acceptable excipients include one or more of ethanol, potassium dihydrogen phosphate or disodium hydrogen phosphate.

Images